Simple Summary
Yttrium-90 radioembolization is used for certain liver tumors, and accurate measurement of the radiation delivered to tumors and healthy organs is essential for evaluating treatment effectiveness and safety. However, conventional imaging techniques have limitations in accurately estimating radiation doses, particularly in small lesions. Long axial field-of-view positron emission tomography (PET) scanners have recently emerged as a promising alternative, potentially offering more precise measurements and improved image quality. This narrative review summarizes the available evidence on the use of these scanners for measuring radiation doses after yttrium-90 therapy, with a focus on quantitative accuracy, imaging protocols, and comparisons with conventional imaging methods. Current findings suggest that this technology may improve dose estimation while allowing shorter imaging times. These advances could support more reliable treatment assessment and contribute to the development of personalized therapeutic strategies. Further multicenter studies are needed to confirm its clinical value and support its integration into routine practice.
Abstract
Background/Objectives: long axial field-of-view (LAFOV) PET systems have recently emerged as a promising tool for improving quantitative imaging after [90Y] radionuclide therapy. This narrative review summarizes the current literature evidence on this field of research. Methods: a literature review was performed to identify studies evaluating the clinical application of LAFOV PET for [90Y] dosimetry, focusing on quantitative accuracy, protocol optimization, and comparison with conventional imaging systems. The search was performed on PubMed/MEDLINE, Scopus, and Embase; it was updated until 15 June 2026. A total of 37 papers were extracted and finally 5 papers were selected to be included in the review. Results: even if limited, available evidence seems to indicate that LAFOV PET provides improved quantitative accuracy, lower image noise, and superior dose recovery compared with conventional SAFOV PET, particularly for small lesions. Optimized reconstruction protocols allow acquisition times to be reduced to 20 or even 5 min without significantly affecting dosimetric accuracy, whereas 1-min acquisitions remain suboptimal because of increased image noise. LAFOV PET also enables reliable tumor, liver, and lung dosimetry, with measured tumor absorbed doses generally showing good agreement with pre-treatment predictions. Compared with post-treatment SPECT, LAFOV PET provides comparable organ dosimetry while offering improved quantitative performance. Conclusions: current evidence seems to support the use of LAFOV PET as a valuable technique for accurate post-treatment [90Y] dosimetry. Further multicenter clinical validation is warranted to facilitate its routine implementation in clinical practice.